Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 2, 2018, primarily to furnish a press release announcing its financial and operating results for the second quarter ended June 30, 2018. This filing provides investors with key performance indicators and updates on the company's financial condition for the period. The press release, attached as Exhibit 99.1, contains the detailed results that are central to understanding the company's recent performance and outlook. While the 8-K itself is brief, the furnished press release is the critical document for investors seeking information on Regeneron's Q2 2018 performance. Investors should review Exhibit 99.1 for specifics on revenue, earnings, product sales, pipeline developments, and any forward-looking statements made by the company. The filing's purpose is to ensure timely disclosure of these important operational and financial updates to the market.
Key Highlights
- 1Regeneron announced its second quarter 2018 financial and operating results via a press release filed with the SEC.
- 2The press release, dated August 2, 2018, is attached as Exhibit 99.1 to the 8-K filing.
- 3This filing serves to provide investors with timely updates on the company's performance for the quarter ended June 30, 2018.
- 4Investors should refer to Exhibit 99.1 for detailed financial and operational performance data.
- 5The information furnished under Item 2.02 is not considered 'filed' for certain SEC provisions, but is crucial for market understanding.